A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Immunity to infection reflects a balance: excessive immune responses cause immunopathology (tissue damage, shock), while inadequate responses allow pathogen overgrowth and death. Th1/Th17 responses are often protective against intracellular pathogens but can cause tissue fibrosis and granuloma formation (TB). Th2/eosinophil responses protect against helminths but cause allergic disease. Understanding this balance is critical for distinguishing protective vaccination from harmful immune enhancement.
Compare immunological response to different pathogen classes (bacteria, viruses, parasites, fungi). Study antibody-dependent enhancement in dengue and its mechanism.
Higher antibody titers do not always equal better protection; antibody-mediated enhancement can increase pathology. Th1 responses are not universally 'good'; they can drive chronic inflammation and fibrosis.
From your study of host-pathogen interactions and the adaptive immune response, you know that the immune system deploys different arms — Th1, Th2, Th17, cytotoxic T cells, antibodies — depending on the type of pathogen. What immunopathology teaches is that the immune response itself can become the disease. The damage a patient suffers during an infection is often not caused by the pathogen directly destroying tissue, but by the immune system's inflammatory response overshooting its target and injuring the host's own cells. Understanding when immunity protects and when it harms is central to clinical immunology.
Consider tuberculosis as a paradigm. *Mycobacterium tuberculosis* lives inside macrophages, so the immune system mounts a Th1/IFN-γ response to activate those macrophages and contain the bacteria. This response walls off the infection in granulomas — organized structures of macrophages, giant cells, and T cells. The granuloma is protective: it contains the pathogen. But the same inflammatory response that builds the granuloma also causes caseous necrosis at its center, and if the granuloma breaks down (as it can in immunosuppressed patients), massive tissue destruction and cavity formation in the lung follow. The pathology the patient experiences — coughing, hemoptysis, lung cavitation — is driven by the immune response, not by bacterial toxins. This is immunopathology in its clearest form.
The balance tips differently for different pathogen classes. Helminth infections require Th2 and IgE responses — eosinophils, mast cells, and mucus production — to expel worms from mucosal surfaces. But an excessive or misdirected Th2 response produces allergic disease: asthma, eosinophilic inflammation, and fibrosis. For viral infections, cytotoxic CD8+ T cells are essential for clearing infected cells, but in hepatitis B, it is the CD8+ T cell attack on infected hepatocytes — not the virus itself, which is noncytopathic — that causes liver damage. Patients with weak immune responses can carry hepatitis B asymptomatically for years; it is the immune flare that produces clinical hepatitis.
Perhaps the most dangerous form of immunopathology is antibody-dependent enhancement (ADE), best understood in dengue fever. Dengue has four serotypes. Antibodies generated against one serotype can bind a different serotype without neutralizing it — instead, the antibody-virus complex is taken up more efficiently by Fc-receptor-bearing cells, increasing viral replication and driving a severe inflammatory cascade that can cause hemorrhagic fever and shock. This means that a second dengue infection can be *more* dangerous than the first, precisely because the patient has pre-existing antibodies. ADE is why dengue vaccine development has been so challenging: a vaccine that generates non-neutralizing antibodies against some serotypes could make subsequent natural infection worse rather than better. The lesson generalizes: more immunity is not always better immunity, and the quality, specificity, and balance of the response matter as much as its magnitude.
No topics depend on this one yet.